Association between Visual Acuity and Medical and Non-Medical Costs in Patients with Wet Age-Related Macular Degeneration in France, Germany and Italy

• Published in: Drugs & aging 2008-01, Vol.25 (3), p.255-268
• Main Authors: Bandello, Francesco, Augustin, Albert, Sahel, José-Alain, Benhaddi, Hicham, Negrini, Cristina, Hieke, Klaus, Berdeaux, Gilles H.
• Format: Article
• Language: English
• Subjects: Aged; Analysis of Variance; Biological and medical sciences; Cost of Illness; Cross-Sectional Studies; Data Collection; Fees and Charges; Female; France - epidemiology; Geriatrics/Gerontology; Germany - epidemiology; Health Care Costs - statistics & numerical data; Health Expenditures - statistics & numerical data; Home Care Services - economics; Humans; Internal Medicine; Italy - epidemiology; Macular Degeneration - economics; Macular Degeneration - epidemiology; Male; Medical sciences; Medicine; Medicine & Public Health; Ophthalmology; Original Research Article; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Retinopathies; Severity of Illness Index; Visual Acuity
• ISSN: 1170-229X; 1179-1969
• DOI: 10.2165/00002512-200825030-00007

Introduction Exudative (‘wet’) age-related macular degeneration (ARMD) is the major cause of blindness in Western developed countries. Treatments aimed at preserving vision are already available and new compounds are under development. Micro-economics information will be pivotal to justifying forthcoming investment. Objective This study sought to investigate the costs of exudative ARMD in patients who were actively treated at ophthalmology referral centres in three European countries: France, Germany and Italy. Method This cross-sectional observational study was conducted in France, Germany and Italy in 2004. The following data were collected: ARMD description, visual acuity (VA), and the medical and non-medical resources used for ARMD in the preceding year. The economic perspective was that of society. ANOVA for cost variables estimated the impact of ARMD per eye, adjusted for sex and age. Both hospital and ambulatory eye centres were included. Patients with exudative ARMD were stratified into four levels of severity using VA thresholds of 20/200 for the worst eye (WE) and 20/40 for the best eye (BE). The main outcome measure was medical and non-medical costs. Results 360 patients were included (females 60%; mean age 77 years; mean interval since diagnosis 2.3 years). The two groups with the greatest difference in severity of VA loss consisted of BE ≥20/40, WE ≥20/200 (27.2% of patients) and BE